Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis-Reference-Cited by-同舟云学术

Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis

Published:2020-08-20 Issue:9 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Al-Shaer Mohammad H.¹^ORCID,Märtson Anne-Grete²,Alghamdi Wael A.³^ORCID,Alsultan Abdullah⁴,An Guohua⁵,Ahmed Shahriar⁶,Alkabab Yosra⁷,Banu Sayera⁶,Houpt Eric R.⁷,Ashkin David⁸,Griffith David E.⁹,Cegielski J. Peter⁹,Heysell Scott K.⁷,Peloquin Charles A.¹^ORCID

Affiliation:

1. Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA

2. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

3. Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia

4. Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA

5. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

6. Infectious Diseases Division, International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b), Dhaka, Bangladesh

7. Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA

8. TB Control Section, Division of Disease Control and Health Protection, Florida Department of Health, Tallahassee, Florida, USA

9. University of Texas Health Science Center at Tyler, Tyler, Texas, USA

Abstract

Ethionamide (ETA), an isonicotinic acid derivative, is part of the multidrug-resistant tuberculosis (MDR-TB) regimen. The current guidelines have deprioritized ETA because it is potentially less effective than other agents. Our aim was to develop a population pharmacokinetic (PK) model and simulate ETA dosing regimens in order to assess target attainment. This study included subjects from four different sites, including healthy volunteers and patients with MDR-TB. The TB centers included were two in the United States and one in Bangladesh.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00713-20

Reference23 articles.

1. WHO. 2019. WHO global tuberculosis report 2019. WHO Geneva Switzerland.

2. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

3. Efficacy and tolerability of ethionamide versus prothionamide: a systematic review

4. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

5. Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting polyketide synthase 13 for the treatment of tuberculosis;European Journal of Medicinal Chemistry;2023-11

2. Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients;Antimicrobial Agents and Chemotherapy;2022-09-20

3. Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients;Antimicrobial Agents and Chemotherapy;2021-09-17

4. Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug‐resistant tuberculosis;British Journal of Clinical Pharmacology;2021-03-10

5. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems;Expert Opinion on Drug Metabolism & Toxicology;2020-11-08